Reversibility
Investigating the temporary nature of the permeability change.
Brain drug delivery. Rethought.
We’re developing a non-invasive way to help medicines cross the blood-brain barrier. Without redesigning the medicine.
How it worksThe blood-brain barrier restricts many medicines from reaching brain tissue. Apertum explores a temporary change in that barrier’s permeability.
Non-invasive stimulation is designed to create a temporary delivery window.
The proposed workflow pairs priming with systemic administration of the therapeutic.
Study whether more of the therapeutic reaches the central nervous system.
Preclinical. Building toward translation.
The platform’s research spans rodent, porcine and non-human-primate models. Clinical safety and benefit still need to be established.
Explore the evidenceInvestigating the temporary nature of the permeability change.
Studying barrier access in a larger animal model.
AAV–ARSA proof-of-concept: measuring enzyme activity in brain tissue.
For teams working on CNS therapeutics
We’re looking to connect with biotech and pharma teams, research laboratories and investors exploring better access to the brain.